期刊文献+

非小细胞肺癌中TRIM25和PKM2蛋白表达 被引量:9

Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer
在线阅读 下载PDF
导出
摘要 目的检测临床非小细胞肺癌(Non-small cell lung cancer,NSCLC)病人组织中TRIM25、PKM2蛋白的表达情况,探讨它们的关联性及意义。方法应用组织免疫荧光法,检测TRIM25、PKM2蛋白在60例NSCLC组织和20例癌旁边正常肺组织(>5 cm)表达情况,同时运用Western blotting方法检测TRIM25、PKM2在10例新鲜NSCLC组织中表达情况,并结合标本的临床病理特征进行分析。结果 TRIM25在60例非小细胞肺癌组织中的阳性表达率45%,而20例癌旁正常肺组织中仅为10%(P=0.005)。TRIM25在腺癌中阳性表达率为28.6%,而在鳞癌中为59.4%(P=0.017)。TRIM25被发现与TNM分期、淋巴结转移之间呈正相关性(P<0.05)。PKM2在60例非小细胞肺癌组织中表达率为73.3%,而在20例癌旁正常肺组织中为30%(P=0.001)。PKM2在腺癌的表达为57.1%,而在鳞癌中为87.5%(P=0.008)。通过关联性分析TRIM25和PKM2存在相关性(P=0.026)。Western blot结果表明当TRIM25表达升高时PKM2表达增长放缓。结论 TRIM25、PKM2蛋白可能同时参与到NSCLC发生发展过程中,存在负相关性。 Objective To investigate the expression of tripartite- motif protein 25(TRIM25) and pyruvate kinase M2(PKM2)protein in non- small cell lung cancer(NSCLC) and explore their role in the occurrence and progression of NSCLC. Methods The expressions of TRIM25 and PKM2 protein were detected in 60 NSCLC specimens and 20 adjacent normal lung tissue(5cm from the lesions) with immunofluorescence histochemical method and in 10 fresh specimens of NSCLC with Western blotting. The results were analyzed in relation with the clinicopathological features of the patients. Results The positivity rates of TRIM25 expression was 45% in the 60 lung carcinoma specimens, significantly higher than that in the 20 normal lung tissues(10%, Ρ=0.005). TRIM25 protein was expressed in 28.6% of lung adenocarcinoma tissues and in 59.4% of squamous carcinoma tissues(Ρ =0.017). TRIM25 protein expression was positively correlated with the TNM stages and lymph node metastasis of NSCLC(Ρ0.05). The expressions of PKM2 protein in 60 cases of lung carcinoma was 73.3%,while in 20 cases of normal lung tissues the expressions was 30%(Ρ =0.001). The positivity rates of PKM2 expression differed significantly between lung adenocarcinoma and squamous carcinoma(57.1% vs 87.5%, Ρ=0.008). An inverse correlation was noted between TRIM25 and PKM2 expressions(Ρ =0.026). Conclusion TRIM25 and PKM2 protein may participate in the occurrence and progression of NSCLC, and their expressions are inversely correlated.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2015年第3期437-441,共5页 Journal of Southern Medical University
基金 重庆市卫生局医学科研重点项目
关键词 TRIM25蛋白 PKM2蛋白 癌细胞增殖 免疫荧光组织化学 WESTERN BLOT tripartite-motif protein 25 pyruvate kinase M2 non-small cell lung cancer immunofluorescence Western blotting
  • 相关文献

参考文献13

  • 1秦霞,邱宗荫,邱峰,粟林,屈灿.人肺腺癌耐药细胞株A549/CDDP中相关泛素化蛋白质研究[J].第三军医大学学报,2012,34(9):866-869. 被引量:3
  • 2Mcnab FW, Rajsbaum R, Stoye JP. Tripartite-motif proteins and innate immune regulation [J]. Curt Opin Immunol, 2011, 23(1): 46-56.
  • 3Rajsbaum FM. Jonathan P StoyeAnne O'garra. Tripartite-motif proteins and innate immune regulation [J]. Curt Opin Immunol, 2011, 23(1): 46-56.
  • 4Nakamura Y, Oshima K, Naoi Y, et al. 14-3-3 sigma expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers[J]. Breast Cancer Res Treat, 2012, 134(1): 229-36.
  • 5Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer[J]. Trends Biochem Sci, 2012, 37(8): 309-16.
  • 6Qin X, Chen S, Qiu Z, et al. Proteomic analysis of ubiquitination- associated proteins in a cisplatin-resistant human lung adeno- carcinoma cell line[J], lnt J Mol Med, 2012, 29(5): 791-800.
  • 7Oh YT, Yue P, Zhou W, et al. Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co- activation of ERK and JNK signaling[J]. J Biol Chem, 2012, 287 (1): 257-67.
  • 8Herquel B, Ouararhni K, Khetchoumian K, et al. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma [J]. Proc Natl Acad Sci USA, 2011,108(20): 8212-7.
  • 9Ketscher L, Basters A, Prinz M, et al. mHERC6 is the essential ISG15 E3 ligase in the murine system [J]. Biochem Biophys Res Commun, 2012, 417(1): 135-40.
  • 10Irene C, Aki M, Colmenares SU, et al. Double-strand breaks inheterochromatin move outside of a dynamic HPI a domain to complete recombinational repair[J]. Cell, 2011, 144(5): 732-44.

二级参考文献13

  • 1杨东叶,刘凯于,余泽华.泛素连接酶E3[J].细胞生物学杂志,2005,27(3):281-285. 被引量:16
  • 2饶敏,张淑玲,熊莉娟.蛋白酶体抑制剂MG132诱导肿瘤细胞凋亡机制的研究进展[J].医学分子生物学杂志,2005,2(4):298-301. 被引量:10
  • 3厉明,梅同华.肺癌新标志——肿瘤M2型丙酮酸激酶[J].国际检验医学杂志,2006,27(5):446-447. 被引量:9
  • 4Foo J,Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules[J].Journal of Theoretical Biology,2010,(02):179-188.
  • 5Triller N,Korosec P,Kern I. Multidrug resistance in small cell lung cancer:expression of P-glycoprotein,multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease[J].Lung Cancer,2006,(02):235-240.
  • 6Yang X J. Multisite protein modification and intramolecular signaling[J].Oncog,2005,(10):1653-1662.
  • 7Kannicht C. Post-translational Modifications of Proteins-Tools for Functional Proteomics[M].Totowa:Humana Press,2008.109-131.
  • 8Hjerpe R,Rodriguez M S. Efficient approaches for characterizing ubiquitinated proteins[J].Biochcm Soc Trans,2008,(Pt 5):823-827.
  • 9Guo W,Zhang Y,Chen T. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model[J].Journal of Cancer Research and Clinical Oncology,2011,(01):65-72.
  • 10Garcia-Gonzalo F R,Cruz C,Munoz P. Interaction between HERC1 and M2-type pyruvate kinase[J].FEBS Letters,2003,(1/3):78-84.

共引文献2

同被引文献75

  • 1孙德彬,留静.顺铂联合吉西他滨对肺癌PD-1/PD-L1途径的影响[J].中国生化药物杂志,2014,34(5):50-53. 被引量:12
  • 2肖俊辉,陈玉川.蛋白质降解与死亡时间推断的初步研究[J].法医学杂志,2005,21(2):110-112. 被引量:11
  • 3Christie DA, Lemke CD, Elias IM, et al. Stomatin-like protein 2 binds cardiotipin and regulates mitochondrial biogenesis and func- tion[J]. Mol Cell Biol, 2011, 31(18) :3845-3856.
  • 4Wang Y, Cao W, Yu Z, et al. Downregulation of a mitochondria associated protein SLP-2 inhibits tumor cell motility, proliferation and enhances cell sensitivity to chemotherapeutic reagents [ J ]. Cancer Biol Ther, 2009, 8(17) :1651-1658.
  • 5Xiao B, Xie Z, Guo L, et al. Stomatin-like protein 2 expression is associated with clinical survival in patients with cervical cancer [J3. Int J Clin Exp Pathol, 2015, 8(2) :1804-1809.
  • 6Liu Z, Yang Y, Zhang Y, et al. Stomatin-like protein 2 is associ- ated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-13 in thyroid cancer cells [J]. Oncol Rep, 2014, 31(1):153-160.
  • 7Watag WX, Lin QF, Shen D, et al. Clinicopathological signifi- cance of SLP-2 overexpression in human gallbladder cancer [ J ]. Tumour Bid, 2014, 35(1) :419-423.
  • 8Cao W, Zhang B, Ding F, et al. Expression of SLP-2 was associ- ated with invasion of esophageal squamous cell carcinoma [ J/ OL ]. PLoS One, 2013 : 2015 -06-20 ]. http ://journals. plos. org/ plosone/article? d= 10.1371/journal.pone.0063890.
  • 9Li XH, He F, Yan SM, et al. Increased expression of stomatin- like protein 2 ( STOML2 ) predicts decreased survival in gastric adetmcarcinoma: a retrospective study[ J]. Med Oncol, 2014, 31 (1) :763.
  • 10Song L, Liu L, Wu Z, et al. Knockdown of stomatin-like protein 2(STOML2) reduces the invasive ability of glioma cells through inhibition of the NF-KB/MMP-9 pathway [ J]. J Pathol, 2012, 226 (3) : 534- 543.

引证文献9

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部